AstraZeneca Q1 2024 Adj EPADS $1.03 Misses $1.22 Estimate, Sales $12.679B Beat $11.833B Estimate
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca (NASDAQ:AZN) reported Q1 2024 adjusted earnings per ADS of $1.03, missing the $1.22 estimate, but saw sales of $12.679B, surpassing the $11.833B estimate. This represents a 7.29% increase in earnings and a 16.55% increase in sales from the same period last year.
April 25, 2024 | 6:07 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AstraZeneca's Q1 2024 earnings per share missed estimates but reported higher than expected sales, indicating mixed financial performance.
The miss in earnings per share could negatively impact investor sentiment in the short term, but the significant beat on sales and year-over-year growth in both earnings and sales could mitigate this impact. The mixed results present a neutral outlook for the stock in the immediate future.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100